KAPUALabs - Nova (Page 273)

As hyperscalers race for compute sovereignty, Meta faces unique regulatory and geopolitical hurdles.

By KAPUALabs

/ 19 Jun 2026

How HBM shortages, a 42% VR slump, and ad shifts reshape Meta's path to 2030.

By KAPUALabs

/ 18 Jun 2026

An in-depth analysis of how Eli Lilly is de-risking its supply chain through US capacity expansion and advanced therapeutic delivery platforms.

By KAPUALabs

/ 18 Jun 2026

With a quick ratio of 2.35, low leverage, and a divided analyst crowd, Meta navigates layoffs and AI ambitions.

By KAPUALabs

/ 18 Jun 2026

A deep dive into Meta's strategy to monetize WhatsApp through subscriptions and AI, facing EU regulatory challenges and security threats.

By KAPUALabs

/ 18 Jun 2026

Examining the Reliance partnership, Reality Labs restructuring, and Reels momentum in Meta's investment landscape.

By KAPUALabs

/ 18 Jun 2026

A comprehensive analysis of Meta's challenges in AI governance, XR interoperability, and cybersecurity in a fragmented landscape.

By KAPUALabs

/ 18 Jun 2026

How Meta's rapid deployment of temporary data centers and custom silicon aims to bypass global compute bottlenecks.

By KAPUALabs

/ 18 Jun 2026

How Meta is transforming its core business through AI-driven advertising and new revenue streams

By KAPUALabs

/ 18 Jun 2026

Examining the clinical evidence, reimbursement shifts, and strategic outlook for the leading GLP-1 therapy.

By KAPUALabs

/ 18 Jun 2026

Trading at 17x forward earnings with 3.56 billion daily users, the market may be overlooking a massive re-rating catalyst.

By KAPUALabs

/ 18 Jun 2026

The growing regulatory landscape for AI-generated content is reshaping digital advertising and impacting Meta's core business model.

By KAPUALabs

/ 18 Jun 2026